BRAXIA SCIENTIFIC LAUNCHES PSILOCYBIN-ASSISTED CLINICAL THERAPY TRAINING PROGRAM
BRAXIA SCIENTIFIC LAUNCHES PSILOCYBIN-ASSISTED CLINICAL THERAPY TRAINING PROGRAM TO DEVELOP NEW GENERATION OF QUALIFIED PHYSICIANS, PSYCHOTHERAPISTS AND PSYCHOLOGISTS FOR MENTAL HEALTH TORONTO, ONTARIO June 29, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce it has launched its psilocybin-assisted clinical therapy training program. Through this program, Braxia will develop, train and support a new generation of qualified, skilled in best practices independent medical physicians, psychologists and psychotherapists to implement safe and effective psilocybin-assisted therapy for patients with depression. The therapists will participate in the provision of psychotherapy in upcoming clinical trials at Braxia evaluating the safety and efficacy of psilocybin in depression. The Company anticipates that, pending regulatory approval of psilocybin, therapists would also be...